Dr. Correa discusses her work on brain tumors and genetics, and their contribution to adverse side effects.
In this video, Denise Correa, MD, discusses her work on brain tumors and genetics, and their contribution to adverse side effects.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.